Clinical trials: Severe Knee Pain
Osteoarthritis, Knee, Osteoarthritis, Hip
To Assess the Patients' Ability to Self-Administer Fasinumab
The primary objective is to demonstrate that the auto-injector(AI) is suitable to be used to administer fasinumab at home by patients or their caregivers, as measured by collecting 12 weeks of actual-use data on the technical…
- Trial name
- FACT DEVICE (NCT03491904)
- Testing
- Fasinumab AI, Fasinumab PFS
- Where
- 23 sites in United States
- Volunteers
- 100 people
- Sponsor
- Regeneron Pharmaceuticals
Knee Osteoarthritis, Knee Pain Chronic
Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OA
It is hypothesized that a single Intra-articular Injection of TTAX03, 100mg in 2mL of saline, will have more benefit with respect to the proportion of responders 12 weeks post-injection than an equal volume of saline, based on…
- Conditions
- Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis
- Trial name
- NCT05079035
- Testing
- TTAX03, Saline
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- BioTissue Holdings, Inc
Knee Osteoarthritis
A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee
A study to assess safety, tolerability and clinical effects of single and repeat dose intra-articular administration of UBX0101 in patients with moderate to severe painful knee osteoarthritis (OA).
- Trial name
- NCT04229225
- Testing
- UBX0101
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- Unity Biotechnology, Inc.
Pain, Nausea
A Multi-Center Actual-Use Study on the Safety of CL 108 for the Treatment of Moderate to Severe Acute Pain Associated With Osteoarthritis of the Knee or Hip
The purpose of CLCT-006, a multi-center open-label study, is to evaluate the safety of CL-108 (hydrocodone 7.5 mg/APAP 325 mg, promethazine 12.5 mg) for the treatment of moderate to severe acute pain ("flare") associated with…
- Conditions
- Pain, Nausea, Vomiting
- Trial name
- NCT02462850
- Testing
- CL-108
- Where
- United States
- Volunteers
- 178 people
- Sponsor
- Charleston Laboratories, Inc
Osteoarthritis, Knee, Pain, Knee
Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis
This study evaluates the safety of resiniferatoxin in patients with moderate to severe knee pain due to osteoarthritis.
- Trial name
- NCT03542838
- Testing
- Resiniferatoxin, Saline
- Where
- 4 sites in United States
- Volunteers
- 94 people
- Sponsor
- Sorrento Therapeutics, Inc.
Osteoarthritis, Osteoarthritis, Hip
A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain
The purpose of this study is to compare the safety and effectiveness of different doses of JNJ-42160443 with placebo in the treatment of chronic, moderate to severe knee or hip pain in patients with a diagnosis of osteoarthritis.
- Conditions
- Osteoarthritis, Osteoarthritis, Hip, Osteoarthritis, Knee, Pain
- Trial name
- NCT00973141
- Testing
- JNJ-42160443
- Where
- 77 sites in United States, Canada and 2 more
- Volunteers
- 467 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Osteoarthritis, Knee, Knee Osteoarthritis
Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis
This study evaluates the efficacy and safety of a single IA injection of various RTX doses, Zilretta or placebo for the treatment of pain due to moderate to severe osteoarthritis knee pain..
- Conditions
- Osteoarthritis, Knee, Knee Osteoarthritis, Knee Pain Chronic
- Trial name
- NCT04885972
- Testing
- Resiniferatoxin, Zilretta
- Where
- 6 sites in United States
- Volunteers
- 124 people
- Sponsor
- Sorrento Therapeutics, Inc.
Severe Knee Pain, Severe Knee Disability
Persona Revision Knee System EMEA PMCF Study
The purpose of this post-market clinical follow-up study is to confirm the long-term safety, performance and clinical benefits of the Persona Revision Knee System Implants and Instrumentation in revision Total Knee Arthroplasty.
- Conditions
- Severe Knee Pain, Severe Knee Disability, Revision Arthroplasty
- Trial name
- NCT07843966
- Where
- 2 sites in Denmark, Spain
- Volunteers
- 238 people
- Sponsor
- Zimmer, GmbH
Osteoarthritis, Knee
A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee
A study to evaluate safety, tolerability, and pharmacokinetics of a single intra-articular injection of UBX0101 in patients diagnosed with painful osteoarthritis of the knee.
- Trial name
- NCT03513016
- Testing
- UBX0101
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- Unity Biotechnology, Inc.
Chronic Pain, Osteoarthritis
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability.
The main objective of the study is to evaluate the effectiveness, tolerability, and safety of tapentadol hydrochloride prolonged release (PR) in participants suffering from severe chronic pain due to osteoarthritis of the knee…
- Trial name
- NCT00982280
- Testing
- Tapentadol PR
- Where
- 24 sites in Australia, Denmark and 4 more
- Volunteers
- 82 people
- Sponsor
- Grünenthal GmbH
Osteoarthritis
A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee
The primary aim is to assess if PF-00592379 is able to reduce pain in patients with osteoarthritis of the knee.
- Trial name
- NCT00483977
- Testing
- Oxycodone, PF-000592379
- Where
- 21 sites in United States
- Volunteers
- 113 people
- Sponsor
- Pfizer
Osteoarthritis, Knee / Osteoarthritis, Hip
Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain
The objective of this study is to verify the superiority of 16 weeks of MT-5547 treatment to placebo, as evidenced by the WOMAC pain score (the efficacy outcome measure), in patients with osteoarthritis of the knee or hip.
- Trial name
- NCT03245008
- Testing
- MT-5547
- Where
- 27 sites in Japan
- Volunteers
- 626 people
- Sponsor
- Tanabe Pharma Corporation
Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain
The purpose of this study is to evaluate the safety and efficacy of GRT6005 compared to placebo in patients with moderate to severe chronic pain due to osteoarthritis (OA) of the knee.
- Trial name
- NCT01709214
- Testing
- Cebranopadol (GRT6005) Low-Dose Range, Cebranopadol (GRT6005) High-Dose Range, Oxycodone CR
- Where
- 83 sites in United States
- Volunteers
- 619 people
- Sponsor
- Tris Pharma, Inc.
Osteoarthritis
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Multiple Subcutaneous Doses of OLP-1002
This is a Phase 1b, randomised, double-blind, placebo-controlled, parallel study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of multiple SC doses of OLP-1002 in patients who have pain due to…
- Trial name
- NCT04677933
- Testing
- A: OLP-1002, B: OLP-1002
- Where
- 4 sites in Australia
- Volunteers
- 30 people
- Sponsor
- OliPass Australia Pty Ltd
Osteoarthritis, Knee
A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee
To evaluate the safety and tolerability of single IV doses of PF-04383119 in Japanese patients with moderate to severe pain from OA of the knee (Part I).
- Trial name
- NCT00669409
- Testing
- PF-04383119 (tanezumab)
- Where
- 12 sites in Japan
- Volunteers
- 83 people
- Sponsor
- Pfizer
Osteoarthritis of the Knee
Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee
The purpose of this study is to determine the efficacy of ADL5859 versus placebo and ADL5747 versus placebo in relieving pain in participants with osteoarthritis of the knee.
- Trial name
- NCT00979953
- Testing
- ADL5859, ADL5747, Oxycodone CR
- Where
- 11 sites in United States
- Volunteers
- 408 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Severe Knee Pain, Severe Knee Disability
Zimmer POLAR Persona - TKA (EMEA Study)
The primary objective of this study is to obtain implant survivorship and clinical outcomes data for commercially available Persona knee implants used in primary total knee arthroplasty. The assessment will include: 1.
- Conditions
- Severe Knee Pain, Severe Knee Disability, Osteoarthritis, Rheumatoid Arthritis
- Trial name
- NCT02337244
- Testing
- Zimmer Persona Total Knee System
- Where
- 12 sites in Austria, France and 4 more
- Volunteers
- 777 people
- Sponsor
- Zimmer, GmbH
Osteoarthritis, Osteoarthritis, Knee
A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis
The purpose of this study is to evaluate pain relief, safety, and tolerability of a new treatment (JNJ-42160443) for moderate to severe pain of osteoarthritis of the knee in comparison to a standard pain treatment and placebo.
- Conditions
- Osteoarthritis, Osteoarthritis, Knee, Pain, Arthralgia
- Trial name
- NCT01094262
- Testing
- Oxycodone CR (standard pain medication), JNJ-42160443
- Where
- 44 sites in United States, Canada
- Volunteers
- 196 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pain, Chronic Back Pain
An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)
The purpose of this study is to evaluate tapentadol Extended Release (ER) in the treatment of moderate to severe chronic pain in participants with a diagnosis of chronic low back pain (LBP) or osteoarthritis (OA) of the hip or…
- Conditions
- Pain, Chronic Back Pain, Chronic Low Back Pain, Osteoarthritis Pain In The Hip or Knee
- Trial name
- NCT01631513
- Testing
- Nucynta ER
- Where
- 7 sites in United States
- Sponsor
- Janssen Scientific Affairs, LLC
Osteoarthritis, Knee
An Open-Label Long-term Safety Study of Tramadol HCl OAD (Once A Day) 300 mg in the Treatment of Pain Due to Osteoarthritis of the Knee
The purpose of this study is to collect information regarding the long-term (6 and 12 months) safety of Tramadol HCl Once-A-Day(OAD) 300 mg.
- Trial name
- NCT00833911
- Testing
- Tramadol Once A Day
- Volunteers
- 392 people
- Sponsor
- Labopharm Inc.